Heart failure looks better on paper but is it really gone? In this episode, we explore the landmark TRED HF trial and why a recovered ejection fraction in dilated cardiomyopathy often represents remission rather than cure. Nearly 40% of patients relapsed within six months of stopping therapy, and that risk rose to 65% over five years, sometimes even after medications were restarted at lower doses. We discuss why cardiac imaging and biomarkers still cannot reliably identify who can safely stop treatment. The message is clear: for most patients, continuing guideline directed medical therapy (GDMT) remains essential to protect the heart and prevent relapse.